InMed regains Nasdaq minimum bid price compliance; deficiency closed

InMed Pharmaceuticals Inc.

Received Nasdaq notice on June 3, 2026 that bid price was at or above $1.00 for 10 consecutive business days (May 19–June 2).
Previously notified of deficiency on March 27, 2026 for bid price below $1.00 for 30 consecutive days.
Nasdaq has closed the matter; Company remains listed on the Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.